Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading.

The Toyota Production System is a paradox. On the one hand, every activity, connection, and production flow in a Toyota factory is rigidly scripted. Yet at the same time, Toyota's operations are enormously flexible and responsive to customer demand. How can that be? After an extensive four-year study of the system in more than 40 plants, the authors came to understand that at Toyota it's the very rigidity of the operations that makes the flexibility possible. That's because the company's operations can be seen as a continuous series of controlled experiments. Whenever Toyota defines a specification, it is establishing a hypothesis that is then tested through action. This approach--the scientific method--is not imposed on workers, it's ingrained in them. And it stimulates them to engage in the kind of experimentation that is widely recognized as the cornerstone of a learning organization. The Toyota Production System grew out of the workings of the company over 50 years, and it has never actually been written down. Making the implicit explicit, the authors lay out four principles that show how Toyota sets up all its operations as experiments and teaches the scientific method to its workers. The first rule governs the way workers do their work. The second, the way they interact with one another. The third governs how production lines are constructed. And the last, how people learn to improve. Every activity, connection, and production path designed according to these rules must have built-in tests that signal problems immediately. And it is the continual response to those problems that makes this seemingly rigid system so flexible and adaptive to changing circumstances.

learning objective:

To articulate and apply the four tacit rules that make the Toyota production system successful.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

Considers whether New Balance, one of the world's five largest manufacturers of athletic footwear, should respond to Adidas' planned acquisition of Reebok-a transaction that would join the second- and third-largest companies in the industry. Highlights the unique aspects of New Balance's strategy-focusing on fit and performance by offering long-lived shoes in a wide variety of widths and eschewing celebrity endorsement of its products-and discusses New Balance's operations decisions to support that strategy. These include significant use of domestic manufacturing at a time when nearly all other competitors sourced finished shoes from Asian suppliers and an emphasis on improving inventory management for its network of small and large retailers. Set just after the announcement of the Adidas-Reebok transaction in 2005, with New Balance having recently initiated a companywide effort to improve operational performance through the application of concepts from lean manufacturing and the Toyota Production System. Asks students to consider whether New Balance should change aspects of its operations strategy in light of the consolidation among its competitors or whether the Adidas-Reebok transaction represents an opportunity for New Balance to emphasize the importance of moving forward with its current approach.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

Peter Schultz, Professor of Chemistry at The Scripps Research Institute, managed an extremely productive lab. This case examines how Schultz recruited, motivated and inspired the students and scientists that worked with him.

learning objective:

Illustrate effective management of a science lab in a university setting.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train clinical investigators.

learning objective:

To understand the role of clinical research within the spectrum of biomedical research.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

To maximize their effectiveness, color cases should be printed in color.

Symyx is a science-based company spun out of Berkeley. Its unique materials technology has been exploited for 10 years, but the company needs a new business model. The company concept required the invention of hardware and software to do high throughput materials discovery, and a business partnership model to support the scientific and engineering development. The public company must now find new ways to grow, and Isy Goldwasser, a co-founder and new CEO, must lead the transition while maintaining unique scientific resources.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

Dr. Bradford Shingleton has developed some of the highest quality eye surgery techniques in the industry. He involves his nurses and technicians in creating a surgical service that is constantly improving. The case has many details about how Dr. Shingleton works with his staff and patients, and how the provider team focuses on patient care. A key measure of productivity for the surgery center is the time required in the operating room. Shingleton's numbers are impressive as they decrease each year. The business context relates to the particular patients, mostly require cataract or glaucoma surgery and the payer is Medicare/Medicaid, which regulates the price. Yearly decreasing prices make it more difficult for doctors to earn a good income unless they improve their productivity. Other surgeons in the practice do not copy Dr. Shingleton's practices nor use his trained surgical team. The dilemma relates to why his methods do not spread to other doctors and other clinics.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

The executive team at Corning has committed to double the rate of new business creation per decade, while at the same time growing the company's current businesses, including glass substrates for LCD displays. Their strategy, built on more than 150 years of successful innovation, is to invent "keystone components" which uniquely enable other companies' products and earn high margins from its proprietary technology. As part of the company's mission to be around for another 150 years, the executive team is also committed to devote considerable resources to basic research "in faith" that it will create new, high-margin businesses that will drive corporate growth in 10-20 years and enable the company to "reinvent" itself, even though they will not be around to reap the benefits of this investment. The executive team must choose how to allocate finite RD&E resources between (1) "pushing" one, or more, of four brand new businesses with considerable potential in the development pipeline to the market sooner; (2) allocating more resources to six new products being launched from existing businesses; or (3) spending more on exploratory research. In making these decisions, the executive team must consider the impact of their decision on not only near-term earnings, but on how it will enable Corning to diversify over the medium to long term in terms of the quality and quantity of its portfolio of new technologies in the development pipeline and new businesses being launched, especially so that it is not overly dependent on sales of a particular business like LCD glass.

learning objective:

Leadership qualities and processes to run a science-based innovation company.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007, corporate R&D spending was $6.43B, or almost 17% of net sales. Novartis executive leaders believe in scientific progress and that large-scale investments in science will therefore result in long-term pay-offs in terms of profits and discoveries that benefit mankind. Novartis' business strategy is closely tied to its research strategy, which emphasizes extensive internal discovery and development capabilities leading to organic growth along with explicit external alliances and collaborations to supplement its core capabilities. Like its competitors, Novartis faces many challenges in terms of moving research from the bench to the bedside. Five years after undertaking the restructuring of the discovery research organization, CEO Daniel Vasella is pleased with its progress, including many more development projects in the pipeline and new molecular entities. Nevertheless, the company faces a number of challenges, including generic drugs, patent infringements in developing countries, and pricing pressure from governments and health insurers in the United States. Given these challenges, Novartis must decide how much to spend on R&D overall, how to arrive at the right mix between organic growth and external collaboration and in-licensing, and how to measure success when it takes so many years to develop and launch a successful drug.

learning objective:

Strategy for creating breakthrough science and technology for business advantage; importance of collaboration.

Source:

Product number:

Length:

Also Available in:

description

Translating Innovative ideas from the clinician to the patient remains a major problem in the field of medicine. Dr. John Parrish and colleagues created an organization (CIMIT) that brings the technical, financial, and administrative resources to these innovative clinicians and facilitates the development of the ideas so they eventually become medical practice. While successful on many dimensions, Parrish is faced with the dilemma of stable, longterm funding and an understanding of how to replicate CIMIT at other locations around the globe.

Publication Date:

Discipline:

Source:

Product number:

Length:

Also Available in:

description

This case is available in only hard copy format (HBP does not have digital distribution rights to the content). As a result, a digital Educator Copy of the case is not available through this web site.

Computer science departments were new to universities in the 1960s, and the one created at the University of Utah by David Evans and Ivan Sutherland had a research mission to invent the field of computer graphics. Details the research process that led to many of the critical breakthrough concepts and algorithms for the field and the training of PhDs, who then created companies that brought the new technology to the marketplace.

learning objective:

To explore building an organization that creates the underlying science for a new industry.

*required field. You can change details at any time before activation.

The enrollment number will not limit students' access to materials. Accurate enrollment allows
us to manage site traffic and course activity.

If your course is affiliated with an institution not listed here or you need to create a course to last longer than 6 months,
please contact HBP Customer Service at custserv@hbsp.harvard.edu or 800-545-7685.

Type the information in each box. Boxes marked with an asterisk (*) are required information.
You can change the coursepack information, including the Start and Stop Dates and the quantity,
at any time before you activate the coursepack.

If your coursepack is affiliated with an institution not listed here or you need to create a coursepack
which is longer than 6 months, please contact HBP Customer Service at custserv@hbsp.harvard.edu
or 800-545-7685.